Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly To Buy Alnara And Its Non-Porcine Pancreatic Enzyme Replacement Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

Alnara hopes to leverage Lilly's prior success with recombinant insulin products.
Advertisement

Related Content

Alcresta Infused With $10M Series B To Get First Product To Market
What's That Drug Called?
Lilly's Solpura Advisory Committee Could Hinge On Manufacturing Issues
Lilly's Pancreatic Enzyme Replacement Therapy Faces Advisory Committee Scrutiny
On Q3 Earnings Call, Lilly Vows To Stay Its Current Course Despite Late-Stage Pipeline Setbacks
Biotech Ventures Forth: Third Rock Rolls Out $426M Fund, Relypsa Reloads
Pfizer Adds To Specialty Care Division With Purchase Of FoldRx
Lilly To Focus Mainly On Pipeline Development As It Faces Steep Patent Cliff
This Little Pig-Free Product Goes To Market? Alnara's High Hopes For A PERT
This Little Pig-Free Product Goes To Market? Alnara's High Hopes For A PERT

Topics

Advertisement
UsernamePublicRestriction

Register

PS070924

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel